Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease

Gary Whitlock; Stephen MacMahon; Craig Anderson; Bruce Neal; Anthony Rodgers; John Chalmers

doi:10.3109/10641969709083190

Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease

Gary Whitlock, Stephen MacMahon, Craig Anderson, Bruce Neal, Anthony Rodgers, John Chalmers

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

Cerebrovascular disease and high blood pressure both appear to increase the risk of vascular dementia. PROGRESS aims to investigate whether blood pressure lowering with an angiotensin converting enzyme inhibitor-based regimen will reduce the risk of cognitive impairment in patients with a history of stroke or transient ischaemic attack. A total of at least 6000 patients will be randomised to receive perindopril (± indapamide) or matching placebo(s), with treatment and follow-up scheduled to continue for at least 4 years. Substudies will investigate the effects of treatment on cognitive decline in subgroups defined by apo-E genotype and on white matter lesions assessed by magnetic resonance imaging. Final results from the study should be available in 2001.

Original language	English
Pages (from-to)	843-855
Number of pages	13
Journal	Clinical and Experimental Hypertension
Volume	19
Issue number	5-6
DOIs	https://doi.org/10.3109/10641969709083190
Publication status	Published - 1997
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10641969709083190Licence: In Copyright

Cite this

@article{37f4b523a454470e93befd6f1eba2238,

title = "Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease",

abstract = "Cerebrovascular disease and high blood pressure both appear to increase the risk of vascular dementia. PROGRESS aims to investigate whether blood pressure lowering with an angiotensin converting enzyme inhibitor-based regimen will reduce the risk of cognitive impairment in patients with a history of stroke or transient ischaemic attack. A total of at least 6000 patients will be randomised to receive perindopril (± indapamide) or matching placebo(s), with treatment and follow-up scheduled to continue for at least 4 years. Substudies will investigate the effects of treatment on cognitive decline in subgroups defined by apo-E genotype and on white matter lesions assessed by magnetic resonance imaging. Final results from the study should be available in 2001.",

author = "Gary Whitlock and Stephen MacMahon and Craig Anderson and Bruce Neal and Anthony Rodgers and John Chalmers",

year = "1997",

doi = "10.3109/10641969709083190",

language = "English",

volume = "19",

pages = "843--855",

journal = "Clinical and Experimental Hypertension",

issn = "1064-1963",

publisher = "Taylor & Francis Group LLC Philadelphia",

number = "5-6",

}

TY - JOUR

T1 - Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease

AU - Whitlock, Gary

AU - MacMahon, Stephen

AU - Anderson, Craig

AU - Neal, Bruce

AU - Rodgers, Anthony

AU - Chalmers, John

PY - 1997

Y1 - 1997

N2 - Cerebrovascular disease and high blood pressure both appear to increase the risk of vascular dementia. PROGRESS aims to investigate whether blood pressure lowering with an angiotensin converting enzyme inhibitor-based regimen will reduce the risk of cognitive impairment in patients with a history of stroke or transient ischaemic attack. A total of at least 6000 patients will be randomised to receive perindopril (± indapamide) or matching placebo(s), with treatment and follow-up scheduled to continue for at least 4 years. Substudies will investigate the effects of treatment on cognitive decline in subgroups defined by apo-E genotype and on white matter lesions assessed by magnetic resonance imaging. Final results from the study should be available in 2001.

AB - Cerebrovascular disease and high blood pressure both appear to increase the risk of vascular dementia. PROGRESS aims to investigate whether blood pressure lowering with an angiotensin converting enzyme inhibitor-based regimen will reduce the risk of cognitive impairment in patients with a history of stroke or transient ischaemic attack. A total of at least 6000 patients will be randomised to receive perindopril (± indapamide) or matching placebo(s), with treatment and follow-up scheduled to continue for at least 4 years. Substudies will investigate the effects of treatment on cognitive decline in subgroups defined by apo-E genotype and on white matter lesions assessed by magnetic resonance imaging. Final results from the study should be available in 2001.

UR - http://www.scopus.com/inward/record.url?scp=0030838821&partnerID=8YFLogxK

U2 - 10.3109/10641969709083190

DO - 10.3109/10641969709083190

M3 - Article

C2 - 9247759

AN - SCOPUS:0030838821

SN - 1064-1963

VL - 19

SP - 843

EP - 855

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

IS - 5-6

ER -

Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this